Microalgae hold great potential towards pharmaceutical and nutraceutical sectors due to their substantial content of highly functional bioactive compounds. To assess their potential as a sustainable source of valuable products, 10 cyanobacterial and 10 eukaryotic microalgal strains belonging to different taxonomic groups (Chlorophyta, Cyanophyta, Euglenophyta, Heterokontophyta and Rhodophyta) were screened for their biochemical profile, antioxidant and antimicrobial activity against Staphylococcus aureus. Total phenol content and antioxidant activity were positively correlated (r = 0.69, p < 0.01), with the highest values observed in Euglena cantabrica, Haematococcus pluvialis, and Chrysoreinhardia giraudii. HPLC-PAD pigment analysis revealed species-specific profiles, with β,β-carotene as major carotenoid in most cyanobacteria, whereas neoxanthin, violaxanthin and lutein were predominantly present in Chlorophyta, and fucoxanthin was the main carotenoid in C. giraudii, Entomoneis sp. and Isochrysis galbana. Protein content ranged from 9.2 ± 0.4% to 57.6 ± 0.5% with the highest levels in the cyanobacteria Microcystis aeruginosa, Nostoc sp., Cylindrospermum stagnale, Anabaena minutissima, and Arthrospira platensis. Multivariate analysis differentiated cyanobacteria and eukaryotes based on their fatty acid profiles. Organic extracts from 15 species showed inhibitory effects against S. aureus with MIC50 < 1024 µg/mL. The eukaryotes Entomoneis sp., C. giraudii, I. galbana, Picochlorum sp. and the cyanobacteria C. stagnale and Nodularia sp. exhibited the strongest inhibitory effects on bacterial growth. In conclusion, E. cantabrica and C. giraudii stood out for their high antioxidant activity and significant antimicrobial effects, respectively, highlighting their potential as valuable sources of bioactive compounds.
Falco et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: